MJH Life Sciences® reposted this
The recent approval of Moderna’s respiratory syncytial virus (RSV) vaccine mRNA-1345 (mRESVIA) could encourage the use of mRNA technology across different landscapes. "The RSV market landscape has witnessed substantial change in recent years owing to the emergence of novel vaccines and monoclonal antibodies for prophylaxis, and the approval of mRESVIA now represents another important addition," said Anaelle Tannen, infectious disease analyst at GlobalData Plc, in a news release. "The improved options for RSV prophylaxis will benefit physicians by providing more choice and tailoring vaccine administration for the individual." Kennedy Ferruggia has the story for Pharmacy Times: https://bit.ly/45JVM5Z | #mRNAVaccines #Vaccines #HealthTechnology #FDAApprovals #DrugDevelopment MJH Life Sciences®
